Outlook Therapeutics
Outlook Therapeutics
OTLK
NASDAQ
7.35
USD
428.78%
About
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The Company's product candidate, ONS-5010, is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).
Bevacizumab is a full-length, humanized anti-Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE.
The Company sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 132.3K |
| Three Month Average Volume | 4.1M |
| High Low | |
| Fifty-Two Week High | 18 USD |
| Fifty-Two Week Low | 4.004 USD |
| Fifty-Two Week High Date | 19 Oct 2023 |
| Fifty-Two Week Low Date | 08 Sep 2023 |
| Price and Volume | |
| Current Price | 7.35 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -5.09% |
| Thirteen Week Relative Price Change | -2.87% |
| Twenty-Six Week Relative Price Change | -17.74% |
| Fifty-Two Week Relative Price Change | 28.63% |
| Year-to-Date Relative Price Change | -21.23% |
| Price Change | |
| One Day Price Change | 0.68% |
| Thirteen Week Price Change | 3.96% |
| Twenty-Six Week Price Change | -9.55% |
| Five Day Price Change | -2.39% |
| Fifty-Two Week Price Change | 61.18% |
| Year-to-Date Price Change | -6.73% |
| Month-to-Date Price Change | -5.16% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -1.1095 USD |
| Book Value Per Share (Most Recent Quarter) | -3.57493 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -1.1095 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -3.57493 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.72176 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -4.71528 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -8.12375 USD |
| Normalized (Last Fiscal Year) | -4.68526 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -4.71528 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -7.95494 USD |
| Including Extraordinary Items (Last Fiscal Year) | -4.71528 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -8.12375 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.7976 USD |
| Cash Per Share (Most Recent Quarter) | 1.36823 USD |
| Cash Flow Per Share (Last Fiscal Year) | -4.71175 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -5.7146 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -3.92642 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -2,681 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -3,125.87% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -3,009.66% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -3,043.92% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | 10.15% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 208.29% |
| EPS Change (Trailing Twelve Months) | -60.30% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 407.6K |
| Net Debt (Last Fiscal Year) | 12.2M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 1 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -42,973,400 |
| Free Cash Flow (Trailing Twelve Months) | -64,553,280 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -34 |
| Net Interest Coverage (Trailing Twelve Months) | -27 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -193.93% |
| Return on Assets (Trailing Twelve Months) | -205.48% |
| Return on Assets (5 Year) | -214.69% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -1,843.48% |